The Cancer Developmental Biology Lab aims to understand how aberrant activation of embryonic signalling pathways contributes to the initiation, growth and self-renewal of cancer. We use a diverse range of model systems in several different tumour types to create a preclinical research
program that has made significant discoveries in cancer biology. These include genetically modified mouse models, and patient-derived xenografts. Key aspects of our research have generated direct translational outcomes in cancer therapy. Most notably, the use of Hedgehog (Hh) pathway inhibitors
for the treatment of medulloblastoma is based directly on the work of our laboratory, and that of our international collaborators. By combining data generated from human tissue samples, cell lines and genetic mouse models, we hope to facilitate pathway discovery, and to identify new therapeutic
opportunities. More recently, we have begun to dissect the mechanisms behind tumour regeneration, and the genomic origins of acquired resistance to chemotherapy. We undertake research on lung and breast cancers, sarcomas and cancers of childhood.
No References for this article.
No Supplementary Data.
No Article Media
CANCERS OF CHILDHOOD;
Document Type: Research Article
Publication date: October 1, 2017
More about this publication?
Impact is a series of high-quality, open access and free to access science reports designed to enable the dissemination of research impact to key stakeholders. Communicating the impact and relevance of research projects across a large number of subjects in a content format that is easily accessible by an academic and stakeholder audience. The publication features content from the world's leading research councils, policy groups, universities and research projects. Impact is published under a CC-BY Creative Commons licence.
- Subscribe to this Title
- Terms & Conditions
- Disseminating research in Impact
- Information about Impact
- Ingenta Connect is not responsible for the content or availability of external websites